Geron faces uphill battle at FDA meeting as agency questions benefit-risk profile of imetelstat

With 99% of patients experiencing an adverse event, the FDA is skeptical that the risks associated with Geron’s myelodysplastic syndromes (MDS) medicine imetelstat outweigh the potential benefit of treatment, particularly in patients with lower-risk cases of the blood cancer.